Eisai's Alzheimer's drug Leqembi brought in ¥61.5bn in the six months to 30 September 2026, up 49.7% on a year earlier, according to the company's interim earnings release. In the Americas segment, which covers North America, Leqembi sales were ¥32.7bn, up 69.8%.
The US launch
In August 2026 Eisai began selling LEQEMBI IQLIK, a subcutaneous auto-injector version of Leqembi, in the US as an initial therapy. The release says the US approved the initial-therapy regimen (500 mg weekly) in July 2026. China and Japan followed in September, and applications are pending in four countries. A weekly maintenance dose of the auto-injector (360 mg) was already approved in the US. The release gives no sales figure for IQLIK alone. It also does not tie the first-half growth to the new formulation, so the launch and the sales rise should be read side by side, not as cause and effect. Earlier Tokyo Brief coverage
Group results and guidance
Group revenue was ¥470bn, up 17.5%, and operating profit was ¥41.4bn, up 20.4%. Eisai credits the cancer drug Lenvima, Leqembi and the insomnia drug Dayvigo, plus a weaker yen, for the revenue rise.
Eisai kept its forecast for the year to March 2027 as set on 15 May 2026: revenue of ¥883.5bn and operating profit of ¥70bn. The interim release states that it is not subject to review by an auditor.